Martingale Asset Management L P Has $1.14 Million Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Martingale Asset Management L P grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 109.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,561 shares of the company's stock after purchasing an additional 12,826 shares during the quarter. Martingale Asset Management L P's holdings in LivaNova were worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Nordea Investment Management AB lifted its position in shares of LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after buying an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in LivaNova in the 4th quarter worth approximately $1,954,000. KBC Group NV grew its holdings in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after purchasing an additional 1,424 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after buying an additional 899 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LIVN shares. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Barclays lowered their price objective on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Friday, March 7th. Finally, The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $61.17.

LivaNova Price Performance

LIVN traded up $0.24 during midday trading on Thursday, reaching $35.31. 196,469 shares of the company's stock were exchanged, compared to its average volume of 624,678. LivaNova PLC has a one year low of $32.48 and a one year high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The business has a 50-day simple moving average of $40.59 and a two-hundred day simple moving average of $47.00. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 84.07 and a beta of 0.90.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.